FiercePharma

Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval For New Higher-Dose Aricept® (Donepezil HCl) 23 mg Tablet

Woodcliff Lake, NJ, and New York, July 23, 2010 - Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...
EurekAlert!

First-of-its-kind study of vascular dementia patients taking ARICEPT® presented at AAGP meeting

ARICEPT® efficacy and safety study in new treatment area presented at the American Association for Geriatric Psychiatry's (AAGP) 15th annual meeting Orlando, Florida (February 26, 2002) - Treatment ...
EurekAlert!

Two new studies showed Alzheimer's disease treatment beneficial in other memory-related conditions

Honolulu, Hawaii (April 4, 2003) - New data provide the first evidence that ARICEPT® (donepezil HCl tablets) may have potential in treating two dementia-related illnesses beyond Alzheimer's disease ...
Medindia

Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals

TOKYO and WOODCLIFF LAKE, N.J., March 28 Eisai Co., Ltd.and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announced thatthe United States District Court for the District of New Jersey ...
Medindia

U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing

TOKYO and WOODCLIFF LAKE, N.J., Dec. 27 - Eisai Co., Ltd.(Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc.(Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) ...